- Home
- FATE vs ESPR Comparison
FATE vs ESPR Comparison
Compare FATE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- ESPR
- Stock Information
- Founded
- FATE 2007
- ESPR 2008
- Country
- FATE United States
- ESPR United States
- Employees
- FATE N/A
- ESPR N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- ESPR Health Care
- Exchange
- FATE Nasdaq
- ESPR Nasdaq
- Market Cap
- FATE 108.2M
- ESPR 305.0M
- IPO Year
- FATE 2013
- ESPR 2013
- Fundamental
- Price
- FATE $0.94
- ESPR $1.50
- Analyst Decision
- FATE Hold
- ESPR Buy
- Analyst Count
- FATE 9
- ESPR 7
- Target Price
- FATE $5.50
- ESPR $6.36
- AVG Volume (30 Days)
- FATE 3.4M
- ESPR 3.5M
- Earning Date
- FATE 03-05-2025
- ESPR 03-04-2025
- Dividend Yield
- FATE N/A
- ESPR N/A
- EPS Growth
- FATE N/A
- ESPR N/A
- EPS
- FATE N/A
- ESPR N/A
- Revenue
- FATE $13,631,000.00
- ESPR $332,314,000.00
- Revenue This Year
- FATE N/A
- ESPR $5.51
- Revenue Next Year
- FATE N/A
- ESPR $1.42
- P/E Ratio
- FATE N/A
- ESPR N/A
- Revenue Growth
- FATE N/A
- ESPR 185.66
- 52 Week Low
- FATE $0.87
- ESPR $1.47
- 52 Week High
- FATE $7.70
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- FATE 37.74
- ESPR 34.95
- Support Level
- FATE $0.87
- ESPR $1.57
- Resistance Level
- FATE $1.03
- ESPR $1.86
- Average True Range (ATR)
- FATE 0.12
- ESPR 0.13
- MACD
- FATE -0.01
- ESPR -0.01
- Stochastic Oscillator
- FATE 13.12
- ESPR 7.69
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.